| Literature DB >> 33087841 |
Debottam Sinha1,2, Purba Nag1,2,3, Devathri Nanayakkara1, Pascal H G Duijf4,5, Andrew Burgess6, Prahlad Raninga1, Veronique A J Smits7,8,9, Amanda L Bain1, Goutham Subramanian1, Meaghan Wall10, John W Finnie11, Murugan Kalimutho12, Kum Kum Khanna13.
Abstract
High expression of centrosomal protein CEP55 has been correlated with clinico-pathological parameters across multiple human cancers. Despite significant in vitro studies and association of aberrantly overexpressed CEP55 with worse prognosis, its causal role in vivo tumorigenesis remains elusive. Here, using a ubiquitously overexpressing transgenic mouse model, we show that Cep55 overexpression causes spontaneous tumorigenesis and accelerates Trp53+/- induced tumours in vivo. At the cellular level, using mouse embryonic fibroblasts (MEFs), we demonstrate that Cep55 overexpression induces proliferation advantage by modulating multiple cellular signalling networks including the hyperactivation of the Pi3k/Akt pathway. Notably, Cep55 overexpressing MEFs have a compromised Chk1-dependent S-phase checkpoint, causing increased replication speed and DNA damage, resulting in a prolonged aberrant mitotic division. Importantly, this phenotype was rescued by pharmacological inhibition of Pi3k/Akt or expression of mutant Chk1 (S280A) protein, which is insensitive to regulation by active Akt, in Cep55 overexpressing MEFs. Moreover, we report that Cep55 overexpression causes stabilized microtubules. Collectively, our data demonstrates causative effects of deregulated Cep55 on genome stability and tumorigenesis which have potential implications for tumour initiation and therapy development.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33087841 PMCID: PMC7578791 DOI: 10.1038/s42003-020-01304-6
Source DB: PubMed Journal: Commun Biol ISSN: 2399-3642